Gerhard Opelz1, Bernd Döhler. 1. Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany. Gerhard.Opelz@med.uni-heidelberg.de
Abstract
BACKGROUND: There have been striking changes during the last 10 years concerning the choice of calcineurin inhibitor and antimetabolite agent prescribed after kidney transplantation. METHODS: A retrospective analysis of 51,303 patients undergoing deceased-donor kidney transplantation during 1998 to 2007 was performed using multivariate regression analysis. All patients received cyclosporine A (CsA) or tacrolimus (Tac) with azathioprine (AZA) or mycophenolic acid (MPA) on an intention-to-treat basis with corticosteroids plus/minus antibody induction. Graft survival rates and secondary outcomes were analyzed. A subanalysis was performed for transplants undertaken during 2002 to 2007, in which all patients were treated with MPA plus corticosteroids and CsA or Tac. RESULTS: All-cause graft failure and death-censored graft failure to 5 years posttransplant did not differ significantly between Tac and CsA. We found no evidence in support of previous claims that MPA results in superior long-term graft survival compared with AZA treatment. At the end of year 1, Tac was associated with a lower risk for serum creatinine more than or equal to 130 mumol/L (P<0.001) and hypercholesterolemia (P<0.001) versus CsA, but a higher risk for de novo posttransplant diabetes (P<0.001). MPA treatment was associated with a lower risk of acute rejection (P<0.001) but a higher risk of hospitalization because of infection (P<0.001) versus AZA. CONCLUSIONS: Five-year graft survival in deceased-donor kidney transplant recipients is equivalent in patients receiving CsA- or Tac-based immunosuppression, and in those receiving MPA or AZA. The absence of a survival benefit with modern agents is relevant in the current cost-conscious era of prescribing.
BACKGROUND: There have been striking changes during the last 10 years concerning the choice of calcineurin inhibitor and antimetabolite agent prescribed after kidney transplantation. METHODS: A retrospective analysis of 51,303 patients undergoing deceased-donor kidney transplantation during 1998 to 2007 was performed using multivariate regression analysis. All patients received cyclosporine A (CsA) or tacrolimus (Tac) with azathioprine (AZA) or mycophenolic acid (MPA) on an intention-to-treat basis with corticosteroids plus/minus antibody induction. Graft survival rates and secondary outcomes were analyzed. A subanalysis was performed for transplants undertaken during 2002 to 2007, in which all patients were treated with MPA plus corticosteroids and CsA or Tac. RESULTS: All-cause graft failure and death-censored graft failure to 5 years posttransplant did not differ significantly between Tac and CsA. We found no evidence in support of previous claims that MPA results in superior long-term graft survival compared with AZA treatment. At the end of year 1, Tac was associated with a lower risk for serum creatinine more than or equal to 130 mumol/L (P<0.001) and hypercholesterolemia (P<0.001) versus CsA, but a higher risk for de novo posttransplant diabetes (P<0.001). MPA treatment was associated with a lower risk of acute rejection (P<0.001) but a higher risk of hospitalization because of infection (P<0.001) versus AZA. CONCLUSIONS: Five-year graft survival in deceased-donor kidney transplant recipients is equivalent in patients receiving CsA- or Tac-based immunosuppression, and in those receiving MPA or AZA. The absence of a survival benefit with modern agents is relevant in the current cost-conscious era of prescribing.
Authors: Michael E Seifert; Muthukumar Gunasekaran; Timothy A Horwedel; Reem Daloul; Gregory A Storch; Thalachallour Mohanakumar; Daniel C Brennan Journal: J Am Soc Nephrol Date: 2016-11-07 Impact factor: 10.121
Authors: Emilio Rodrigo; Gema Fernández-Fresnedo; Carmen Robledo; Rosa Palomar; Carmen Cantarell; Auxiliadora Mazuecos; Antonio Osuna; Alicia Mendiluce; Antonio Alarcón; Manuel Arias Journal: NDT Plus Date: 2010-06
Authors: L Quteineh; P-Y Bochud; D Golshayan; S Crettol; J-P Venetz; O Manuel; Z Kutalik; A Treyer; R Lehmann; N J Mueller; I Binet; C van Delden; J Steiger; P Mohacsi; J-F Dufour; P M Soccal; M Pascual; C B Eap Journal: Pharmacogenomics J Date: 2015-12-08 Impact factor: 3.550
Authors: Gere Sunder-Plassmann; Petra Reinke; Thomas Rath; Andrzej Wiecek; Michal Nowicki; Richard Moore; Jens Lutz; Martina Gaggl; Marek Ferkl Journal: Transpl Int Date: 2012-04-16 Impact factor: 3.782